FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114312013> ?p ?o ?g. }

• W2114312013 endingPage "8" @default.
• W2114312013 startingPage "611" @default.
• W2114312013 abstract "A Phase Ib trial of bryostatin 1, a macrocyclic lactone and protein kinase C (PKC) activator, was conducted in patients with refractory nonhematological malignancies with the primary goal of determining whether down-regulation of peripheral blood mononuclear cell (PBMNC) PKC activity could be achieved in vivo in humans. Patients (four patients/cohort) received bryostatin 1 (25 microg/m2) as a 1-h infusion weekly three times every 4 weeks, but to study the schedule dependence of pharmacokinetics and pharmacodynamics, the first dose was administered according to one of three schedules: (a) a 1-h infusion; (b) a 24-h infusion; or (c) a split course (12.5 microg/m2 as a 30-min infusion) on days 1 and 4. Conventional toxicities (grades I-III) included myalgias, fever, anemia, fatigue, phlebitis, and headache; in addition, two patients in cohort 3 experienced transient elevations in liver function tests, although these patients had preexisting liver metastases. No objective clinical responses were encountered. Effects on PBMNC PKC activity were heterogeneous. Several patients in cohorts 1 and 2 experienced significant declines in activity (approximately 50%) that were sustained in some cases for periods of > or = 72 h. Comparison of 72-h with baseline values for all three patient cohorts combined revealed a trend toward PKC down-regulation (P = 0.06; signed rank test). For each schedule, plasma bryostatin 1 levels were below the level of detection of a platelet aggregation-based bioassay (3-4 nm). Bryostatin 1 administration failed to produce consistent alterations in lymphocyte immunophenotypic profiles, interleukin 2-induced proliferation, or cytotoxicity, although two of three samples from patients in cohort 3 did show significant posttreatment increases in proliferation. Moreover, in some patients, bryostatin 1 treatment increased lymphokine-activated killer cell activity. These findings indicate that bryostatin 1 doses of 25 microg/m2 can induce in vivo PBMNC PKC down-regulation in at least a subset of patients and raise the possibility that higher bryostatin 1 doses may be more effective in achieving this effect." @default.
• W2114312013 created "2016-06-24" @default.
• W2114312013 creator A5010854687 @default.
• W2114312013 creator A5030965906 @default.
• W2114312013 creator A5045307639 @default.
• W2114312013 creator A5050307933 @default.
• W2114312013 creator A5055228684 @default.
• W2114312013 creator A5061036144 @default.
• W2114312013 creator A5064069772 @default.
• W2114312013 creator A5091632652 @default.
• W2114312013 date "1998-03-01" @default.
• W2114312013 modified "2023-09-27" @default.
• W2114312013 title "Phase Ib trial of bryostatin 1 in patients with refractory malignancies." @default.
• W2114312013 cites W1480069833 @default.
• W2114312013 cites W1496644503 @default.
• W2114312013 cites W1544430323 @default.
• W2114312013 cites W1570282298 @default.
• W2114312013 cites W1579942173 @default.
• W2114312013 cites W1580291739 @default.
• W2114312013 cites W1588356042 @default.
• W2114312013 cites W1606913060 @default.
• W2114312013 cites W1790739196 @default.
• W2114312013 cites W1937458778 @default.
• W2114312013 cites W1967439648 @default.
• W2114312013 cites W1977525265 @default.
• W2114312013 cites W1981880855 @default.
• W2114312013 cites W1989859193 @default.
• W2114312013 cites W2004308413 @default.
• W2114312013 cites W2006817479 @default.
• W2114312013 cites W2007069751 @default.
• W2114312013 cites W2012179870 @default.
• W2114312013 cites W2038905259 @default.
• W2114312013 cites W2047047872 @default.
• W2114312013 cites W2069855944 @default.
• W2114312013 cites W2069873423 @default.
• W2114312013 cites W2101647884 @default.
• W2114312013 cites W2116403966 @default.
• W2114312013 cites W2126544407 @default.
• W2114312013 cites W2127254301 @default.
• W2114312013 cites W2137637658 @default.
• W2114312013 cites W2138727941 @default.
• W2114312013 cites W2139979468 @default.
• W2114312013 cites W2140879800 @default.
• W2114312013 cites W2146823703 @default.
• W2114312013 cites W2148906835 @default.
• W2114312013 cites W2153990155 @default.
• W2114312013 cites W2163792469 @default.
• W2114312013 cites W2166030036 @default.
• W2114312013 cites W2415372781 @default.
• W2114312013 cites W2429694548 @default.
• W2114312013 cites W2437351780 @default.
• W2114312013 cites W2467949666 @default.
• W2114312013 cites W2468119228 @default.
• W2114312013 cites W3005434895 @default.
• W2114312013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9533528" @default.
• W2114312013 hasPublicationYear "1998" @default.
• W2114312013 type Work @default.
• W2114312013 sameAs 2114312013 @default.
• W2114312013 citedByCount "17" @default.
• W2114312013 countsByYear W21143120132015 @default.
• W2114312013 countsByYear W21143120132017 @default.
• W2114312013 crossrefType "journal-article" @default.
• W2114312013 hasAuthorship W2114312013A5010854687 @default.
• W2114312013 hasAuthorship W2114312013A5030965906 @default.
• W2114312013 hasAuthorship W2114312013A5045307639 @default.
• W2114312013 hasAuthorship W2114312013A5050307933 @default.
• W2114312013 hasAuthorship W2114312013A5055228684 @default.
• W2114312013 hasAuthorship W2114312013A5061036144 @default.
• W2114312013 hasAuthorship W2114312013A5064069772 @default.
• W2114312013 hasAuthorship W2114312013A5091632652 @default.
• W2114312013 hasConcept C111113717 @default.
• W2114312013 hasConcept C112705442 @default.
• W2114312013 hasConcept C126322002 @default.
• W2114312013 hasConcept C150903083 @default.
• W2114312013 hasConcept C170493617 @default.
• W2114312013 hasConcept C207001950 @default.
• W2114312013 hasConcept C26291073 @default.
• W2114312013 hasConcept C2910806222 @default.
• W2114312013 hasConcept C29730261 @default.
• W2114312013 hasConcept C31760486 @default.
• W2114312013 hasConcept C71924100 @default.
• W2114312013 hasConcept C72563966 @default.
• W2114312013 hasConcept C86803240 @default.
• W2114312013 hasConcept C88045685 @default.
• W2114312013 hasConcept C90924648 @default.
• W2114312013 hasConcept C98274493 @default.
• W2114312013 hasConceptScore W2114312013C111113717 @default.
• W2114312013 hasConceptScore W2114312013C112705442 @default.
• W2114312013 hasConceptScore W2114312013C126322002 @default.
• W2114312013 hasConceptScore W2114312013C150903083 @default.
• W2114312013 hasConceptScore W2114312013C170493617 @default.
• W2114312013 hasConceptScore W2114312013C207001950 @default.
• W2114312013 hasConceptScore W2114312013C26291073 @default.
• W2114312013 hasConceptScore W2114312013C2910806222 @default.
• W2114312013 hasConceptScore W2114312013C29730261 @default.
• W2114312013 hasConceptScore W2114312013C31760486 @default.
• W2114312013 hasConceptScore W2114312013C71924100 @default.
• W2114312013 hasConceptScore W2114312013C72563966 @default.

• next